SCHEMBL6789156

SCHEMBL6789156

NC(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 20/20 0.75
CDK1 P06493 16/20 0.75
CCNA2 P20248 15/20 0.75
CCNA1 P78396 15/20 0.75
CCNB1 P14635 14/20 0.75
CCNB2 O95067 12/20 0.75
CCNB3 Q8WWL7 12/20 0.75
NEK2 P51955 1/20 0.60
CCNT1 O60563 3/20 0.56
CDK7 P50613 3/20 0.56
CDK9 P50750 3/20 0.56
CCNH P51946 3/20 0.56
CDK5 Q00535 3/20 0.56
CDK4 P11802 2/20 0.56
CCND1 P24385 2/20 0.56
CCNE1 P24864 2/20 0.56
MNAT1 P51948 2/20 0.56
CDK5R1 Q15078 2/20 0.56
AURKA O14965 1/20 0.56
EIF2AK2 P19525 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644959 1.00 CDK2 (0.75) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6789333 0.91 CDK2 (0.74) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6904174 0.90 CDK2 (0.75) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6790184 0.89 CDK2 (0.75) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6787365 0.89 CDK2 (0.75) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6789620 0.88 CDK2 (0.76) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL6787523 0.87 CDK2 (0.63) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL31439116 0.87 CDK2 (0.72) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL2169233 0.86 CDK2 (0.77) CDK2CDK1CCNA2CCNA1CCNB1
SCHEMBL31060307 0.86 CDK2 (0.77) CDK2CDK1CCNA2CCNA1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110775-A1 Cyclin dependent kinase inhibiting purine derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-06-10 US claimed
EP-1353922-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES Cancer Research Technology Limited (GB) 2003-10-22 EP claimed
WO-2002059125-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-08-01 WO claimed
US-20240034799-A1 METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS CEDARS SINAI MEDICAL CENTER (US) 2024-02-01 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-7970581-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-7970581-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-7970580-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-7970580-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2011-06-28 US disclosed
US-20100241411-A1 Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-23 US disclosed
US-20100241411-A1 Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-23 US disclosed
US-20100241412-A1 Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-23 US disclosed
US-20100241412-A1 Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-23 US disclosed
US-7756674-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2010-07-13 US disclosed
US-7756674-B2 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2010-07-13 US disclosed
US-20090037136-A1 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-05 US disclosed
US-20090037136-A1 Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-05 US disclosed
US-20040110775-A1 Cyclin dependent kinase inhibiting purine derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-06-10 US disclosed
EP-1353922-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES Cancer Research Technology Limited (GB) 2003-10-22 EP disclosed
WO-2002059125-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110775-A1 Cyclin dependent kinase inhibiting purine derivatives CCNA1, CDKL1, CCNK CDK2 13/4885CDK1 4/4885CCNA2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.